Results 91 to 100 of about 25,438 (199)
Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.• STK25 deficiency enhanced CAF‐mediated CRC growth via the NF‐κB/AREG/EGFR axis. • STK25 overexpression or AREG antibody overcame CAF‐mediated cetuximab resistance. • CRC patients with high STK25 and low CAFs marker levels might benefit from cetuximab treatment.
Yifan Hou +17 more
wiley +1 more source
CAR‐T Cells: Current Status, Challenges, and Future Prospects
MedComm, Volume 7, Issue 5, May 2026.This graphical abstract outlines the current status, challenges, and future prospects of CAR‐T cells. The biological basis of CAR‐T cell therapy is the elegant redirection of adaptive immunity. Its initial successes have exposed a landscape of multifaceted challenges.
Aya Sedky Adly +6 more
wiley +1 more source
ADCC: the rock band led by therapeutic antibodies, tumor and immune cells
Frontiers in ImmunologyAntibody-dependent cellular cytotoxicity (ADCC) is a critical mechanism by which therapeutic antibodies leverage the immune system to target and eliminate cancer cells. The key agents of ADCC are natural killer (NK) cells, specifically targeting antibody-
Roos Vincken +4 more
doaj +1 more source
Medicinal Research Reviews, Volume 46, Issue 3, Page 672-712, May 2026.ABSTRACT Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, posing a serious threat, particularly to infants, the elderly, and individuals with compromised immune systems. As the leading cause of lower respiratory tract infections (LRTIs) in infants, RSV is responsible for millions of cases worldwide each year.
Jie Shi +6 more
wiley +1 more source
SARS‐CoV‐2 Variants and Immune Evasion: Mapping the Future of Vaccine Design
Reviews in Medical Virology, Volume 36, Issue 3, May 2026.ABSTRACT The evolutionary trajectory of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) has progressed through several distinct phases since its zoonotic emergence, transitioning from initial human adaptation to an era of rapid antigenic drift and complex immune evasion. As of early 2026, the global landscape is dominated by highly evolved
Fatih Uzer +2 more
wiley +1 more source
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source
The Critical Role of GALNTs‐Regulated O‐GalNAc Glycosylation in Cancer Malignancy
The FASEB Journal, Volume 40, Issue 8, 30 April 2026.The GALNT family initiates mucin‐type O‐GalNAc glycosylation in the Golgi apparatus and how regulatory mechanisms, including GALNT relocalization and microRNA control, modulate this process. Dysregulated O‐GalNAc glycosylation alters key cellular behaviors and promotes cancer malignancy, highlighting its relevance to tumor progression as well as its ...
Jiahao Liu +7 more
wiley +1 more source
Glycan pairing in therapeutic IgG orchestrates Fcγ receptor engagement and ADCC: an integrated structure-function approach for thorough evaluation of Fc N-glycans as critical quality attributes. [PDF]
MAbsMeudt M +9 more
europepmc +1 more source
Basaloid-Solid Adenoid Cystic Carcinoma of the Breast: A Case Report and Literature Review. [PDF]
Case Rep PatholZhou Y, Hu Y, Zhang Y.
europepmc +1 more source